Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT01297400
PHASE2

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Sponsor: Skingenix, Inc.

View on ClinicalTrials.gov

Summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2022-03-11

Completion Date

2026-12-31

Last Updated

2026-03-16

Healthy Volunteers

No

Conditions

Interventions

DRUG

Investigational Drug, MW-III

Topical application, twice a day

DRUG

Silvadene® Cream 1% [Silver Sulfadiazine]

Topical application, twice a day

Locations (6)

Valleywise Health Medical Center

Phoenix, Arizona, United States

University of CA Davis Medical Center

Sacramento, California, United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

University of Iowa Health Care

Iowa City, Iowa, United States

Proactive CR Mexico SA de CV

Irapuato, Mexico

SMIQ S de R. L de CV

Querétaro City, Mexico